FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386895314> ?p ?o ?g. }

• W4386895314 abstract "Background Immune cell expression profiling from patient samples is critical for the successful development of immuno-oncology agents and is useful to understand mechanism-of-action, to identify exploratory biomarkers predictive of response, and to guide treatment selection and combination therapy strategies. LAG-3 is an inhibitory immune checkpoint that can suppress antitumor T-cell responses and targeting LAG-3, in combination with PD-1, is a rational approach to enhance antitumor immunity that has recently demonstrated clinical success. Here, we sought to identify human immune cell subsets that express LAG-3 and its ligands, to characterize the marker expression profile of these subsets, and to investigate the potential relationship between LAG-3 expressing subsets and clinical outcomes to immuno-oncology therapies. Methods Comprehensive high-parameter immunophenotyping was performed using mass and flow cytometry of tumor-infiltrating lymphocytes (TILs) and peripheral blood mononuclear cells (PBMCs) from two independent cohorts of samples from patients with various solid tumor types. Profiling of circulating immune cells by single cell RNA-seq was conducted on samples from a clinical trial cohort of melanoma patients treated with immunotherapy. Results LAG-3 was most highly expressed by subsets of tumor-infiltrating CD8 T central memory (TCM) and effector memory (TEM) cells and was frequently co-expressed with PD-1. We determined that these PD-1 + LAG-3 + CD8 memory T cells exhibited a unique marker profile, with greater expression of activation (CD69, HLA-DR), inhibitory (TIM-3, TIGIT, CTLA-4) and stimulatory (4-1BB, ICOS) markers compared to cells that expressed only PD-1 or LAG-3, or that were negative for both checkpoints. In contrast to tumors, LAG-3 expression was more limited in circulating immune cells from healthy donors and solid tumor patients. Additionally, we found abundant expression of the LAG-3 ligands MHC-II and galectin-3 in diverse immune cell types, whereas FGL1 and LSECtin were minimally expressed by immune cells in the tumor microenvironment (TME). Lastly, we found an inverse relationship between baseline and on-treatment levels of circulating LAG3 transcript-expressing CD8 memory T cells and response to combination PD-1 and CTLA-4 blockade in a clinical trial cohort of melanoma patients profiled by scRNAseq. Conclusions These results provide insights into the nature of LAG-3- and ligand-expressing immune cells within the TME, and suggest a biological basis for informing mechanistic hypotheses, treatment selection strategies, and combination immunotherapy approaches to support continued development of dual PD-1 and LAG-3 blockade." @default.
• W4386895314 created "2023-09-21" @default.
• W4386895314 creator A5001281569 @default.
• W4386895314 creator A5012977236 @default.
• W4386895314 creator A5013229878 @default.
• W4386895314 creator A5013526652 @default.
• W4386895314 creator A5015575842 @default.
• W4386895314 creator A5016576278 @default.
• W4386895314 creator A5021741464 @default.
• W4386895314 creator A5034494853 @default.
• W4386895314 creator A5039868500 @default.
• W4386895314 creator A5043429980 @default.
• W4386895314 creator A5044963819 @default.
• W4386895314 creator A5051793744 @default.
• W4386895314 creator A5067777053 @default.
• W4386895314 creator A5088525103 @default.
• W4386895314 date "2023-09-19" @default.
• W4386895314 modified "2023-10-16" @default.
• W4386895314 title "Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands" @default.
• W4386895314 cites W1612601009 @default.
• W4386895314 cites W1910012553 @default.
• W4386895314 cites W1979773132 @default.
• W4386895314 cites W1980137951 @default.
• W4386895314 cites W1981291019 @default.
• W4386895314 cites W1986269759 @default.
• W4386895314 cites W1993835819 @default.
• W4386895314 cites W1998877652 @default.
• W4386895314 cites W2032830977 @default.
• W4386895314 cites W2041143310 @default.
• W4386895314 cites W2047900254 @default.
• W4386895314 cites W2069089843 @default.
• W4386895314 cites W2077116159 @default.
• W4386895314 cites W2117552772 @default.
• W4386895314 cites W2121273824 @default.
• W4386895314 cites W2122689603 @default.
• W4386895314 cites W2128758225 @default.
• W4386895314 cites W2132020367 @default.
• W4386895314 cites W2136807515 @default.
• W4386895314 cites W2139591061 @default.
• W4386895314 cites W2146404779 @default.
• W4386895314 cites W2150492554 @default.
• W4386895314 cites W2155959680 @default.
• W4386895314 cites W2321361127 @default.
• W4386895314 cites W2519279652 @default.
• W4386895314 cites W2537734913 @default.
• W4386895314 cites W2572174216 @default.
• W4386895314 cites W2580464105 @default.
• W4386895314 cites W2587048937 @default.
• W4386895314 cites W2788672255 @default.
• W4386895314 cites W2794480084 @default.
• W4386895314 cites W2807534769 @default.
• W4386895314 cites W2808421749 @default.
• W4386895314 cites W2849303123 @default.
• W4386895314 cites W2896896220 @default.
• W4386895314 cites W2902688986 @default.
• W4386895314 cites W2903754922 @default.
• W4386895314 cites W2906369032 @default.
• W4386895314 cites W2942744719 @default.
• W4386895314 cites W2949177718 @default.
• W4386895314 cites W2951473363 @default.
• W4386895314 cites W2951598503 @default.
• W4386895314 cites W2952815301 @default.
• W4386895314 cites W2979790494 @default.
• W4386895314 cites W2982786601 @default.
• W4386895314 cites W2984472267 @default.
• W4386895314 cites W2990200213 @default.
• W4386895314 cites W3005326482 @default.
• W4386895314 cites W3020888809 @default.
• W4386895314 cites W3037167017 @default.
• W4386895314 cites W3042559121 @default.
• W4386895314 cites W3112462393 @default.
• W4386895314 cites W3164692211 @default.
• W4386895314 cites W3179304282 @default.
• W4386895314 cites W3195744482 @default.
• W4386895314 cites W4223627273 @default.
• W4386895314 cites W4224143573 @default.
• W4386895314 cites W4225394054 @default.
• W4386895314 cites W4285798811 @default.
• W4386895314 cites W4286295255 @default.
• W4386895314 cites W4292229910 @default.
• W4386895314 cites W4296694188 @default.
• W4386895314 doi "https://doi.org/10.3389/fimmu.2023.1151748" @default.
• W4386895314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37795090" @default.
• W4386895314 hasPublicationYear "2023" @default.
• W4386895314 type Work @default.
• W4386895314 citedByCount "0" @default.
• W4386895314 crossrefType "journal-article" @default.
• W4386895314 hasAuthorship W4386895314A5001281569 @default.
• W4386895314 hasAuthorship W4386895314A5012977236 @default.
• W4386895314 hasAuthorship W4386895314A5013229878 @default.
• W4386895314 hasAuthorship W4386895314A5013526652 @default.
• W4386895314 hasAuthorship W4386895314A5015575842 @default.
• W4386895314 hasAuthorship W4386895314A5016576278 @default.
• W4386895314 hasAuthorship W4386895314A5021741464 @default.
• W4386895314 hasAuthorship W4386895314A5034494853 @default.
• W4386895314 hasAuthorship W4386895314A5039868500 @default.
• W4386895314 hasAuthorship W4386895314A5043429980 @default.
• W4386895314 hasAuthorship W4386895314A5044963819 @default.
• W4386895314 hasAuthorship W4386895314A5051793744 @default.
• W4386895314 hasAuthorship W4386895314A5067777053 @default.

• next